-
CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment
•
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on track to obtain priority review statuses. These include Shenyang Sinqi Pharmaceutical Co. Ltd.’s atropine for arresting the progression of myopia in children, Zhuhai Jinzhidun Pharmaceutical Technology Co., Ltd.’s trientine for hepatolenticular degeneration that cannot tolerate…
-
Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a first-in-class intravascular dual mode imaging equipment for coronary artery imaging, has been approved for marketing in China. This marks a significant advancement in the field of cardiovascular diagnostics. Integrating IVUS and OCT TechnologiesThe Novasight Hybrid…
-
HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors
•
China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under this collaboration, HitGen will leverage its DNA-encoded library (DEL) technology platform, which specializes in the design, synthesis, and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also provide support…
-
BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients
•
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max Foundation (Max) to improve access to the Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries. The three-year collaboration aims to enhance access to…
-
Huadong Medicine’s HDM1002 Receives NMPA Approval for Type 2 Diabetes Clinical Trial
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its small molecule drug HDM1002, intended for the treatment of adult type 2 diabetes. This follows closely on the heels of the drug’s approval to enter clinical trials in…
-
Everest Medicines Completes Patient Enrollment in Etrasimod Phase III UC Trial
•
Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient enrollment in a multi-center Phase III clinical trial for etrasimod in Asia, specifically targeting the treatment of moderate-severe active ulcerative colitis (UC). This development follows Everest’s acquisition of development rights to etrasimod in Greater China…
-
HuidaGene Secures US Patent for High-Efficiency Cas12Max DNA Editing System
•
HuidaGene Therapeutics, a China-based biotechnology company, has announced the receipt of patent protection from the US Patent and Trademark Office (USPTO) for its cutting-edge DNA editing system, Cas12Max (CRISPR-Cas12i). This system is recognized for its superior DNA editing efficiency in mammalian cells compared to other competing systems, such as Streptococcus…
-
Jiangsu Hengrui’s SHR0302 Secures Clinical Trial Approval for GVHD Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of another clinical trial approval for its drug candidate SHR0302, which is intended for the treatment of graft versus host disease (GVHD). SHR0302: A Selective JAK1 Inhibitor with Oral Solution PotentialSHR0302 is recognized as a highly…
